Recipharm, a contract development and manufacturing organization, agreed to acquire Arranta Bio, a biotechnology company, from Ampersand Capital Partners, a private equity firm. Financial terms were not disclosed. “We welcome Arranta and its team of experts who boast a strong reputation in the CDMO industry. This acquisition is another important step for us in growing our biologics business and developing a strong presence into the US. We look forward to working closely with the Arranta team, building links across the wider Recipharm organisation to make this business a huge success," Marc Funk, Recipharm CEO.